Silence Therapeutics PLC

Silence Therapeutics plc is a biotechnology company focused on discovering and developing novel molecules that use short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. Its pipeline includes Divesiran (SLN124), in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a), SLN312 for dyslipidemia, SLN365 for hypercholesterolemia, and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007; it was incorporated in 1994 and is headquartered in London, United Kingdom.